Company intelligence / Profile preview
Centus Biotherapeutics
London, United Kingdomcentusbiotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Centus successfully completed the AVANA Phase 3 clinical study demonstrating no clinically meaningful differences in safety, efficacy, and immunogenicity compared to Avastin® in non-small cell lung cancer patients. Their bevacizumab biosimilar Equidacent received European marketing authorization in September 2020.
- Therapeutic areas
- Oncology
- Modalities
- Biosimilarsmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
AstraZenecaFujifilm Kyowa Kirin Biologics
Beyond the preview
Go deeper on Centus Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Centus Biotherapeutics.